Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25362076 | 0.88 | ALDH1A1 (0.51) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL8550317 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL8547303 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL8547301 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL8547307 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL833489 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EFAAHEPHX2CYP2A6 | |
| SCHEMBL15382502 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4EFAAHEPHX2CYP2A6 | |
| SCHEMBL3636729 | 0.78 | ALDH1A1 (0.56) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL510213 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KDM4EFAAHEPHX2FURIN | |
| SCHEMBL8707560 | 0.77 | SLC6A2 (0.53) | EPHX2CHEK2FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | disclosed |
| EP-1824832-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | WEE1, CDKN1A, DDB1 | ALDH1A1 943/4885KDM4E 3151/4885FAAH 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.